Study design of ASPirin in Reducing Events in the Elderly (ASPREE): A randomized, controlled trial

Contemporary Clinical Trials

Volumn 36, Issue 2, 2013, Pages 555-564

  Grimm, R ^a   McNeil, J J ^a   Applegate, W ^a   Beilin, L ^a   Espinoza, S ^a   Johnston, C I ^a   Kirpach, B ^a   Margolis, K ^a   Murray, A ^a   Nelson, M R ^a   Reid, C M ^a   Shah, R ^a,a   Storey, E ^a   Tonkin, A M ^a   Wilson, P ^a   Wolfe, R ^a   Woods, R L ^a   Abhayaratna, W ^a   Ames, D ^a   Cobiac, L ^a   Donnan, G ^a   Gibbs, P ^a   Head, R ^a   Krum, H ^a   Jelnik, M ^a   Malik, M ^a   Williamson, J ^a   Eaton, C ^a   Weissfeld, J ^a   MacRae, F ^a   Rodriguez, L M ^a   Newman, A B ^a   Demons, J ^a   Workman, B ^a   Wood, E ^a   Satterfield, S ^a   Ernst, M ^a   Gilbertson, D ^a   Lockery, J E ^a   Shah, R C ^a,a   Hannah, J ^a   Radziszewska, B ^a   Thomas, A ^a   Gill, G ^a   Jackson, C ^a   Kidd, M ^a   Russell, G ^a   Pressman, G ^a   Figueredo, V ^a   Oberoi, M ^a   Ahmad, M ^a   Krstevska, S ^a   Lawson, C ^a   Katzman, S ^a   Powell, J ^a   Lang, M ^a   Bolin, P ^a   Atlanta, V A ^a   Le, A ^a   Johnson, T ^a   Kruger, D ^a   Obisesan, T ^a   Allard, J ^a   Dodd, K ^a   Ott, B ^a   Pemu, P ^a   Hadley, E ^a   Romashkan, S V ^a   Palaniappan, L ^a   Jose, P ^a   Church, T ^a   Myers, V ^a   Monce, R ^a   Britt, N ^a   Gupta, A ^a   Keller, J ^a   Lewis, B ^a   Shikany, J ^a   Allman, R ^a   Anton, S ^a   Pahor, M ^a   Burns, J ^a   Swerdlow, R ^a   Anderson, H ^a   Wiggins, J ^a   Nyquist, L ^a   Peterson, K A ^a   Tindle, H ^a   Johnson, K C ^a   Womack, C ^a   Birnbaum, L ^a   Nesbitt, S ^a   Volpi, E ^a   Applegate, W B ^a   Flack, J ^a   Ference, B ^a   Singh, M ^a   Lichtenberg, P ^a   Aloia, J ^a   Mikhail, M ^a   Anwarrulah, A A ^a   Trevaks, R E ^a   Fitzgerald, S M ^a   Stocks, N ^a   more..

^a UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Aging; Aspirin; Clinical trial; Dementia; Disability; Primary prevention

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO;

AGED; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DEMENTIA; DEPRESSION; DISABILITY; DOUBLE BLIND PROCEDURE; FATALITY; FEMALE; HUMAN; KATZ INDEX; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MORTALITY; PHYSICAL DISABILITY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; STUDY DESIGN; TREATMENT OUTCOME;

AGING; ASPIRIN; CLINICAL TRIAL; DEMENTIA; DISABILITY; PRIMARY PREVENTION;

ACTIVITIES OF DAILY LIVING; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; AUSTRALIA; CARDIOVASCULAR DISEASES; DEMENTIA; DEPRESSION; DISABLED PERSONS; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; MORTALITY; NEOPLASMS; RISK ASSESSMENT; TABLETS, ENTERIC-COATED; UNITED STATES;

EID: 84887370094     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2013.09.014     Document Type: Article

References (43)

1. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002, 324:71-86. Antithrombotic Trialists Collaboration.
2. Rothwell P.M., Fowkes F.G.R., Belch J.F.F., Ogawa H., Warlow C.P., Meade T.W. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011, 377(9759):31-41.
3. Broe G.A., Grayson D.A., Creasey H.M., Waite L.M., Casey B.J., Bennett H.P., et al. Anti-inflammatory drugs protect against Alzheimer disease at low doses. Arch Neurol 2000, 57(11):1586-1591.
4. De Berardis G., Lucisano G., D'Ettorre A., Pellegrini F., Lepore V., Tognoni G., et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA 2012, 307(21):2286-2294.
5. He J., Whelton P.K., Vu B., Klag M.J. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA 1998, 280(22):1930-1935.
6. Steering Committee of the Physicians' Health Study Research Group Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989, 321(3):129-135.
7. Peto R., Gray R., Collins R., Wheatley K., Hennekens C., Jamrozik K., et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988, 296:313-316.
8. Collaborative Group of the Primary Prevention Project (PPP) Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001, 357:89-95.
9. Hansson L., Zanchetti A., Carruthers S., Dahlof B., Elmfeldt D., Julios S., et al. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351:1755-1762.
10. The Medical Research Council's General Practice Research Framework Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998, 351:233-241.
11. Ridker P.M., Cook N.R., Lee I.-M., Gordon D., Gaziano J.M., Manson J.E., et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005, 352(13):1293-1304.
12. Silagy C.A., McNeil J.J., Bulpitt C.J., Donnan G.A., Tonkin A.M., Worsam B. Rationale for a primary prevention study using low-dose aspirin to prevent coronary and cerebrovascular disease in the elderly. JAGS 1991, 39:484-491.
13. Silagy C.A., McNeil J.J., Donnan G.A., Tonkin A.M., Worsam B., Campion K. The PACE pilot study: 12-month results and implications for future primary prevention trials in the elderly. (Prevention with low-dose aspirin of cardiovascular disease in the elderly). J Am Geriatr Soc 1994, 42(6):643-647.
14. ASPREE Study Group, Nelson M.R., Reid C.M., Beilin L.J., Donnan G.A., Johnston C.I., et al. Rationale for a primary prevention trial in the elderly of low dose aspirin for the prevention of major adverse cardiovascular events and vascular dementia in Australian general practice. ASPirin in Reducing Events in the Elderly (ASPREE). J Drugs Aging 2003, 20(12):897-903.
15. Nelson M., Reid C., Ames D., Beilin L., Donnan G., Gibbs P., et al. Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. Med J Aust 2008, 189:105-109.
16. National Center for Health Statistics.Health, United States With special feature on socioeconomic status and health 2011, [Hyattsville, MD. 2012. Accessed at http://www.cdc.gov/nchs/data/hus/hus11.pdf#024 16 May 2013].
17. Teng E.L., Chui H.C. The Modified Mini-Mental State (3MS) examination. J Clin Psychol 1987, 48(8):314-318.
18. Katz S., Apkon C.A. A measure of primary sociobiological functions. Int J Health Serv 1976, 6:493-507.
19. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, Washington DC. 4th ed.
20. Smith A. Symbol Digit modalities Test (SDMT). Manual (revised) 1982, Western Psychological Services, Los Angeles.
21. Brandt J., Benedict R.H.B. Hopkins Verbal Learning Test - revised 2001, [Odessa, Fla]. PAR (Ed.).
22. Ross T.P. The reliability of cluster and switch scores for the Controlled Oral Word Association Test. Arch Clin Neuropsychol 2003, 18(2):153-164.
23. Radloff L.S. The CES-D scale: a self report depression scale for research in the general population. Appl Psychol Meas 1977, 1:385-401.
24. LIFE Study Investigators, Pahor M., Blair S.N., Espeland M., Fielding R., Gill T.M., et al. Effects of a physical activity intervention on measures of physical performance: results of the Lifestyle Interventions and Independence for Elders Pilot (LIFE-P) Study. J Gerontol A Biol Sci Med Sci 2006, 61(11):1157-1165.
25. Ware J., Kosinski M., Keller S.D. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996, 34(3):220-233.
26. Rosen W.G., Mohs R.C., Davis K.L. A new rating scale for Alzheimer's disease. Am J Psychol 1984, 141(11):1356-1364.
27. D'Elia L.F., Satz P., L.Uchiyama C., White T. Color Trails Test Professional Manual 1996, Psychological Assessment Resources Inc., Odesa, FL.
28. Reid W., Broe G., Creasey H., Grayson D., McCusker E., Bennett H., et al. Age at onset and pattern of neuropsychological impairment in mild early-stage Alzheimer disease: a study of a community-based population. Arch Neurol 1996, 53(10):1056-1061.
29. Inouye S.K., van Dyck C.H., Alessi C.A., Balkin S., Siegal A.P., Horwitz R.I. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med 1990, 113(12):941-948.
30. Galasko D., Bennet D., Sano M., Marson D., Kaye J., Edland S.D. ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials. Alzheimer Dis Assoc Disord 2006, 20(4 Suppl. 3):S152-S169.
31. ASPREE protocol Version 5 accessed at, [on 3 May 2013]. http://www.aspree.org/AUS/aspree-content/aspree-study-details/aspree-materials.aspx.
32. StataCorp Survival analysis and epidemiological tables manual for Stata Statistical Software: release 10 ed 2007, Stata Corporation, TX: College Station.
33. Sankoh A.J., D'Agostino R.B., Huque M.F. Efficacy endpoint selection and multiplicity adjustment methods in clinical trials with inherent multiple endpoint issues. Stat Med 2003, 22(20):3133-3150.
34. Schulz K.F., Grimes D.A. Multiplicity in randomized trials I: endpoints and treatments. Lancet 2005, 365:1348-1353.
35. Little R.J., D'Agostino R., Cohen M.L., Dickersin K., Emerson S.S., Farrar J.T., et al. The prevention and treatment of missing data in clinical trials. N Engl J Med 2012, 367(14):1355-1360.
36. Jennison C., Turnbull B.W. Group sequential tests with applications to clinical trials 2000, Chapman and Hall. C. Hall (Ed.).
37. Ogawa H., Nakayama M., Morimoto T., Uemura S., Kanauchi M., Doi N., et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008, 300(18):2134-2141.
38. Belch J., MacCuish A., Campbell I., Cobbe S., Taylor R., Prescott R., et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008, 337:a1840.
39. Kawas C.H., Katzman R. Epidemiology of dementia and Alzheimer disease. Alzheimer disease 1999, 95-116. Lippincott Williams & Wilkins, Philadelphia. 2nd ed.
40. Tang M.X., Cross P., Andrews H., Jacobs D.M., Small S., Bell K., et al. Incidence of AD in African-Americans, Caribbean Hispanics, and Caucasians in northern Manhattan. Neurology 2001, 56(1):49-56.
41. Hendrie H.C., Ogunniyi A., Hall K.S., Baiyewu O., Unverzagt F.W., Gureje O., et al. Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA 2001, 285(6):739-747.
42. ICD10 ALL, Australia, 1907-2004 - General Record of Incidence of Mortality, GRIM Accessed at, [on 26 February 2013]. http://www.aihw.gov.au/mortality/data.
43. U.S.CDC Statistics Accessed at, [on 26 February 2013]. http://www.cdc.gov/nchs.